{
    "clinical_study": {
        "@rank": "48524", 
        "arm_group": {
            "arm_group_label": "NOV120101 (Poziotinib)", 
            "arm_group_type": "Experimental", 
            "description": "Single arm study with NOV120101(poziotinib)16mg PO daily administration"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this open-label, single-arm, multi-center phase II trial is to evaluate the\n      efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), as a first-line\n      monotherapeutic agent in patients with lung adenocarcinoma harboring EGFR mutation."
        }, 
        "brief_title": "NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adenocarcinoma of Lung Stage IIIB", 
            "Adenocarcinoma of Lung Stage IV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "EGFR TKIs are known as more effective and less toxic medications against EGRF mutated\n      tumors. However, newly acquired resistance to these inhibitors is the inevitable obstacle in\n      continuous treatment with them. To overcome this problem, many new class of TKIs  including\n      NOV120101 (Poziotinib) are developing these days. To evaluate the efficacy of NOV120101\n      (Poziotinib) as a first-line monotherapeutic medication, chemotherapy-na\u00efve patients will\n      participate in this study. Subjects will receive NOV120101 (Poziotinib) 16 mg PO once daily\n      until disease progression or unacceptable toxicity development. Objective response rate\n      (ORR) will be analyzed as the primary endpoint in this trial. Secondary endpoints including\n      PFS rate at 12 months, DCR, PFS, and OS will also be analyzed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patients aged 20 years or older\n\n          2. Pathologically confirmed stage IIIB (unresectable) or IV lung adenocarcinoma\n\n          3. Documented EGFR mutation (e.g., exon 19 deletion, exon 21 L858R, etc.) with tumor\n             tissue\n\n          4. Patients who have 1 or more measurable lesions according to RECIST version 1.1\n\n          5. ECOG performance status 2 or less\n\n          6. Life expectancy of 12 weeks or more\n\n          7. Patients who have adequate hematological, hepatic and renal functions; WBC 4,000 or\n             more per mm3, platelet 100,000 or more per mm3, serum creatinine 1.5 times or less\n             upper limit of normal, AST and ALT 2.5 times or less upper limit of normal, total\n             bilirubin 1.5 times or less upper limit of normal\n\n          8. Patients who give written informed consent voluntarily\n\n        Exclusion Criteria:\n\n          1. Prior systemic chemotherapy, immunotherapy or biological therapy for stage IIIB or IV\n             adenocarcinoma (However, neo or adjuvant chemo, chemoradio or radiotherapy is\n             permitted if at least 6 months has elapsed prior to disease progression)\n\n          2. Prior treatment with small molecules or antibodies targeting EGFR\n\n          3. Patients who received major surgery within 4 weeks before study drug administration\n\n          4. Symptomatic CNS metastases (patients with radiologically and neurologically stable\n             metastases and being off corticosteroids for at least 2 weeks are able to participate\n             in this trial.)\n\n          5. History of other malignancies except effectively treated non-melanoma skin cancers,\n             carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated\n             malignancy that has been in remission for 3 years or more and considered to be cured\n             by investigator's judgment\n\n          6. Known preexisting interstitial lung disease (ILD)\n\n          7. NYHA class III or IV heart failure, uncontrolled hypertension, unstable angina or\n             myocardial infarction within 6 months, poorly controlled arrhythmia or other\n             clinically significant cardiovascular abnormalities at investigator's discretion\n\n          8. Patients whose left ventricle ejection fraction (LVEF) is below the institutional\n             lower limit of normal (if no lower limit of normal is defined in the site, the lower\n             limit is 50 percent)\n\n          9. Patients with known active hepatitis B, HIV infection, or other uncontrolled\n             infectious disease\n\n         10. Clinically significant or recent acute gastrointestinal disorders with diarrhea as a\n             major symptom (e.g., Crohn's disease, malabsorption disorders, CTCAE grade 2 diarrhea\n             or more due to any etiology)\n\n         11. Patients who cannot receive IP by mouth and be diagnosed with clinically significant\n             gastrointestinal disorders which can prevent administration, transit or absorption of\n             the study drug\n\n         12. Pregnancy or breast feeding\n\n         13. Women of childbearing potential (WOCBP) or men who are unwilling to use adequate\n             contraception or be abstinent during the trial and for at least 2 months after the\n             end of treatment\n\n         14. Patients who received other investigational products except gefitinib and erlotinib\n             within 4 weeks before participation\n\n         15. Patients who cannot participate in this trial by investigator's judgment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819428", 
            "org_study_id": "NOV120101-201"
        }, 
        "intervention": {
            "arm_group_label": "NOV120101 (Poziotinib)", 
            "description": "NOV120101 (Poziotinib)16 mg PO once daily until disease progression or unacceptable toxicity development", 
            "intervention_name": "NOV120101 (Poziotinib)", 
            "intervention_type": "Drug", 
            "other_name": [
                "HM781-36B", 
                "Poziotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "EGFR mutation", 
            "Lung Adenocarcinoma", 
            "Firstline therapy", 
            "Second generation of tyrosine kinase"
        ], 
        "lastchanged_date": "March 24, 2013", 
        "location": [
            {
                "contact": {
                    "email": "jymama@ncc.re.kr", 
                    "last_name": "Han, MD, Ph.D"
                }, 
                "contact_backup": {
                    "email": "jslee@ncc.re.kr", 
                    "last_name": "Lee, MD, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Goyang-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "410-769"
                    }, 
                    "name": "National Cancer Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Jiyoun Han, MD, Ph.D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jinsoo Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Heungtae Kim, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Tak Yun, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Youngjoo Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Soohyun Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ekcho@gilhospital.com", 
                    "last_name": "Cho, MD, Ph.D"
                }, 
                "contact_backup": {
                    "email": "gene2001@gilhospital.com", 
                    "last_name": "Kim, MD, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Namdong-Gu", 
                        "country": "Korea, Republic of", 
                        "state": "Incheon,", 
                        "zip": "405-760"
                    }, 
                    "name": "Gachon University Gil Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Eunkyung Cho, MD, Ph.D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yujin Kim, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Heekyung Ahn, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kpark@skku.edu", 
                    "last_name": "Park, MD, Ph.D"
                }, 
                "contact_backup": {
                    "email": "silkahn@skku.edu", 
                    "last_name": "Ahn, MD, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Gangnam-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Keunchil Park, MD, Ph.D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Myungju Ahn, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Yeonhee Park, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jeeyun Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jongmu Sun, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kimdw@snu.ac.kr", 
                    "last_name": "Kim, MD, Ph.D"
                }, 
                "contact_backup": {
                    "email": "heo1013@snu.ac.kr", 
                    "last_name": "Heo, MD, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Jongno-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Dongwan Kim, MD, Ph.D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Daeseog Heo, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sehoon Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Taemin Kim, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bhumsuk Kim, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Seil Go, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Younak Choi, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Seunghoon Beom, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "JaeJoon Han, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Youngjun Cha, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "leedaeho@amc.seoul.kr", 
                    "last_name": "Lee, MD, Ph.D"
                }, 
                "contact_backup": {
                    "email": "swkim@amc.seoul.kr", 
                    "last_name": "Kim, MD, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Songpa-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "136-738"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Sangwe Kim, MD, Ph.D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Daehoo Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jungshin Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jaecheol Lee, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Changmin Choi, MD, Ph.D", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yjmin65@gmail.com", 
                    "last_name": "Min, MD, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Dong-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Ulsan", 
                        "zip": "682-714"
                    }, 
                    "name": "Ulsan University Hospital"
                }, 
                "investigator": {
                    "last_name": "Youngjoo Min, MD, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations", 
        "other_outcome": [
            {
                "description": "to observe pharmacokinetic parameter, inter-individual variability and intra-individual variability considering covariates, demographic factors, influencing PK profile.", 
                "measure": "Population pharmacokinetics (PK) of NOV120101 (Poziotinib)", 
                "safety_issue": "No", 
                "time_frame": "3 months after enrollment of the last subject"
            }, 
            {
                "description": "to observe HGF expression status in plasma and T790M mutation induction status from plasma DNA", 
                "measure": "Subgroup analyses according to the genetic information", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "overall_contact": {
            "email": "jyk1949@ncc.re.kr", 
            "last_name": "Jungyong Kim, MD, Ph.D", 
            "phone": "+82-31-920-2684"
        }, 
        "overall_contact_backup": {
            "email": "jajung@ncc.re.kr", 
            "last_name": "Jina Jung, MA", 
            "phone": "+82-31-920-2776"
        }, 
        "overall_official": {
            "affiliation": "National OncoVenture", 
            "last_name": "Jungyong Jung, MD, Ph.D", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the proportion of patients with complete response (CR) and/or partial response (PR)", 
            "measure": "Objective response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "about 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819428"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "the proportion of patients with complete response (CR) and/or partial response (PR) at 12 months following start of study drug administration.", 
                "measure": "Progression free survival (PFS) rate  at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months after enrollment of the last subject"
            }, 
            {
                "description": "the proportion of patients with CR, PR and/or stable disease (SD)", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "The length of time during and after medication or treatment during which the disease being treated (usually cnacer) does not get worse.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "the time from study drug administration until death from any cause", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Change means the end of treatment minus baseline in each patient", 
                "measure": "Change of quality of life (QoL) measured by EQ-5D questionnaire", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "National OncoVenture", 
        "sponsors": {
            "collaborator": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National OncoVenture", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}